Introducing Cervista HPV
What is Cervista® HPV HR?
Cervista HPV HR is an advanced, molecular diagnostic HPV screening test. Using proprietary Invader® chemistry, Cervista HPV HR screens for the presence of high-risk HPV types. Cervista HPV HR is an FDA-approved Class III In Vitro Diagnostic Device (IVD) indicated for use as a reflex test to an ASC-US Pap test and as a co-test with the ThinPrep® Pap Test in women aged 30 and over. Click here for complete indications and warnings.
How is Cervista HPV HR different than other HPV tests?
The advanced design of the Cervista HPV HR screening test increases accuracy and reliability. In fact, in comparison with other HPV tests, Cervista HPV HR minimizes both the false positive and false negative test results that can result from low-risk cross-reactivity and lack of cellular material.
- Cervista HPV HR does not cross-react with common low-risk strains of HPV, thereby minimizing false positive results and the potential for over-treating patients.
- Cervista HPV HR is the only HPV screening test that uses an internal control to confirm that adequate DNA is present to render a result. Because other tests lack an internal control, they can return a negative result even if the specimen does not have adequate cellularity.
- Cervista HPV HR requires less specimen volume for testing, reducing the number of Quantity Not Sufficient (QNS) results. This means fewer callbacks, reducing the inconvenience for you and your patients.
What is Cervista HPV 16/18 ?
Cervista HPV 16/18 identifies the two most highly oncogenic and persistent high-risk HPV types known to cause high-grade cervical neoplasia. This test allows identification of patients at greatest risk for developing cervical disease.
Why do I need to add HPV testing to my cervical cancer screening protocol?
High-risk HPV testing can be very valuable when determining an individual’s risk of developing cervical cancer. ACOG and ASCCP both note the added benefit of HPV testing for ASCUS Reflex and co-testing for women 30 and over. Recently, the ASCCP released an algorithm for genotyping HPV types 16 and 18 among women 30 and older in order to further assess risk and tailor care. Cervista HPV HR works together with the ThinPrep Pap Test to maximize sensitivity and specificity, providing greater confidence in test results and subsequent treatment decisions.
Cervista® HPV HR Laboratory Professionals
Learn more about the advanced clinical performance and improved workflow offered by Cervista HPV HR in the laboratory.